IBDEI21T ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,249,0)
 ;;=ESTABLISHED PATIENT^1^24
 ;;^UTILITY(U,$J,358.4,250,0)
 ;;=CONSULTATIONS^3^24
 ;;^UTILITY(U,$J,358.4,251,0)
 ;;=POST-OP FOLLOW-UP^4^24
 ;;^UTILITY(U,$J,358.4,252,0)
 ;;=ABRASION w/o INFECTION^1^25
 ;;^UTILITY(U,$J,358.4,253,0)
 ;;=ABRASION w/ INFECTION^2^25
 ;;^UTILITY(U,$J,358.4,254,0)
 ;;=ABSCESS/CELLULITIS^3^25
 ;;^UTILITY(U,$J,358.4,255,0)
 ;;=ACNE^4^25
 ;;^UTILITY(U,$J,358.4,256,0)
 ;;=ALOPEICA^5^25
 ;;^UTILITY(U,$J,358.4,257,0)
 ;;=BURNS^6^25
 ;;^UTILITY(U,$J,358.4,258,0)
 ;;=CANDIDIASIS^7^25
 ;;^UTILITY(U,$J,358.4,259,0)
 ;;=CELLULITIS^8^25
 ;;^UTILITY(U,$J,358.4,260,0)
 ;;=DERMATITIS^9^25
 ;;^UTILITY(U,$J,358.4,261,0)
 ;;=DERMATOPHYTOSIS^10^25
 ;;^UTILITY(U,$J,358.4,262,0)
 ;;=ECZEMA^11^25
 ;;^UTILITY(U,$J,358.4,263,0)
 ;;=EDEMA^12^25
 ;;^UTILITY(U,$J,358.4,264,0)
 ;;=ERYTHEMA^13^25
 ;;^UTILITY(U,$J,358.4,265,0)
 ;;=EXPOSURE TO HEALTH HAZARDS^14^25
 ;;^UTILITY(U,$J,358.4,266,0)
 ;;=FOLLICULITIS^15^25
 ;;^UTILITY(U,$J,358.4,267,0)
 ;;=FURUNCLE^16^25
 ;;^UTILITY(U,$J,358.4,268,0)
 ;;=GRANULOMA^17^25
 ;;^UTILITY(U,$J,358.4,269,0)
 ;;=HERPES^35^25
 ;;^UTILITY(U,$J,358.4,270,0)
 ;;=HISTORY^36^25
 ;;^UTILITY(U,$J,358.4,271,0)
 ;;=ICHTHYOSIS^38^25
 ;;^UTILITY(U,$J,358.4,272,0)
 ;;=INSECT BITE w/o INFECTION^39^25
 ;;^UTILITY(U,$J,358.4,273,0)
 ;;=INSECT BITE w/INFECTION^40^25
 ;;^UTILITY(U,$J,358.4,274,0)
 ;;=KERATOSIS^42^25
 ;;^UTILITY(U,$J,358.4,275,0)
 ;;=LACERATION^44^25
 ;;^UTILITY(U,$J,358.4,276,0)
 ;;=LESION^46^25
 ;;^UTILITY(U,$J,358.4,277,0)
 ;;=LICHENIFICATION^47^25
 ;;^UTILITY(U,$J,358.4,278,0)
 ;;=LUPUS^48^25
 ;;^UTILITY(U,$J,358.4,279,0)
 ;;=MELANOMA^50^25
 ;;^UTILITY(U,$J,358.4,280,0)
 ;;=NAIL DISEASE^53^25
 ;;^UTILITY(U,$J,358.4,281,0)
 ;;=NEOPLASM-BENIGN^54^25
 ;;^UTILITY(U,$J,358.4,282,0)
 ;;=NEOPLASM-IN SITU^56^25
 ;;^UTILITY(U,$J,358.4,283,0)
 ;;=NEOPLASM-OTHER^57^25
 ;;^UTILITY(U,$J,358.4,284,0)
 ;;=NEURODERMATITIS^58^25
 ;;^UTILITY(U,$J,358.4,285,0)
 ;;=PEDICULOSIS^61^25
 ;;^UTILITY(U,$J,358.4,286,0)
 ;;=PITYRIASIS^62^25
 ;;^UTILITY(U,$J,358.4,287,0)
 ;;=PRURITUS^63^25
 ;;^UTILITY(U,$J,358.4,288,0)
 ;;=PSORIASIS^64^25
 ;;^UTILITY(U,$J,358.4,289,0)
 ;;=STASIS^66^25
 ;;^UTILITY(U,$J,358.4,290,0)
 ;;=ULCER^68^25
 ;;^UTILITY(U,$J,358.4,291,0)
 ;;=ULCER-LOWER EXTREMITY^69^25
 ;;^UTILITY(U,$J,358.4,292,0)
 ;;=URTICARIA^70^25
 ;;^UTILITY(U,$J,358.4,293,0)
 ;;=VARICOSE VEINS^71^25
 ;;^UTILITY(U,$J,358.4,294,0)
 ;;=WOUND^73^25
 ;;^UTILITY(U,$J,358.4,295,0)
 ;;="A" MISC DIAGNOSIS^5.1^25
 ;;^UTILITY(U,$J,358.4,296,0)
 ;;="B" MISC DIAGNOSIS^6.1^25
 ;;^UTILITY(U,$J,358.4,297,0)
 ;;="C" MISC DIAGNOSIS^8.1^25
 ;;^UTILITY(U,$J,358.4,298,0)
 ;;="D" MISC DIAGNOSIS^10.1^25
 ;;^UTILITY(U,$J,358.4,299,0)
 ;;="E" MISC DIAGNOSIS^14.1^25
 ;;^UTILITY(U,$J,358.4,300,0)
 ;;="F" MISC DIAGNOSIS^16.1^25
 ;;^UTILITY(U,$J,358.4,301,0)
 ;;="H" MISC DIAGNOSIS^37^25
 ;;^UTILITY(U,$J,358.4,302,0)
 ;;="I" MISC DIAGNOSIS^41^25
 ;;^UTILITY(U,$J,358.4,303,0)
 ;;="K" MISC DIAGNOSIS^43^25
 ;;^UTILITY(U,$J,358.4,304,0)
 ;;="L" MISC DIAGNOSIS^49^25
 ;;^UTILITY(U,$J,358.4,305,0)
 ;;="M" MISC DIAGNOSIS^51^25
 ;;^UTILITY(U,$J,358.4,306,0)
 ;;="N" MISC DIAGNOSIS^59^25
 ;;^UTILITY(U,$J,358.4,307,0)
 ;;="P" MISC DIAGNOSIS^65^25
 ;;^UTILITY(U,$J,358.4,308,0)
 ;;="X" MISC DIAGNOSIS^75^25
 ;;^UTILITY(U,$J,358.4,309,0)
 ;;="V" MISC DIAGNOSIS^72^25
 ;;^UTILITY(U,$J,358.4,310,0)
 ;;="W" MISC DIAGNOSIS^74^25
 ;;^UTILITY(U,$J,358.4,311,0)
 ;;=AFTERCARE CODES^0^25
 ;;^UTILITY(U,$J,358.4,312,0)
 ;;="S" MISC DIAGNOSIS^67^25
 ;;^UTILITY(U,$J,358.4,313,0)
 ;;=CANCER (NOT MELANOMA)^6.5^25
 ;;^UTILITY(U,$J,358.4,314,0)
 ;;=BOIL/FURUNCLE^5.5^25
 ;;
 ;;$END ROU IBDEI21T
